Added Benefit For Orphans Is ‘Fictitious’ Says German HTA Body
Executive Summary
Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.
You may also be interested in...
Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period
Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.
European Parliament Signs Off Regulation To Tackle Medicine Shortages
The legislation will establish a new EU platform for monitoring and reporting medicines shortages.
Scottish Funding OK For Breast Cancer Drugs Tukysa And Enhertu
As well as recommending Seagen’s Tukysa and Daiichi Sankyo/AstraZeneca’s Enhertu, the Scottish Medicines Consortium has given the green light to Leo Pharma’s Adtralza and a new lung cancer indication for AZ’s Tagrisso. Meanwhile, Alexion has failed to make a submission to HTAs in both Scotland and England for a specific indication for Soliris.